Navigation Links
BioNeutral's Ygiene(TM) Hospital Grade Antimicrobial Proven To Be Completely Inert to Steel In Independent Corrosion Testing
Date:8/5/2009

NEWARK, N.J., Aug. 5 /PRNewswire-FirstCall/ -- BioNeutral Group, Inc. ("BioNeutral") (OTC Bulletin Board: BONU), a specialty chemical technology based Life Science Company announced today independent steel corrosion test results conducted at Criterion Chemical. Following an impartial blind testing protocol Ygiene(TM) Hospital Grade Antimicrobial was found to be completely non-corrosive to steel.

Many of today's commercially available antimicrobials and cleaners are corrosive to iron and steel. As confirmed by this independent test, Ygiene(TM) Hospital Grade Antimicrobial was found to be completely inert and not corrosive while all of the following products tested were found to be corrosive: Lysol(R) Disinfectant All Purpose Cleaner 4N1; Odo Ban(R) Silver Formula Germ Control 24; Clorox(R) Anywhere Hard Surface Daily Sanitizer Spray; Lysol(R) Disinfectant Bathroom Cleaner 4N1; Clorox(R) Regular Bleach; and Green Works(TM) Natural Bathroom Cleaner. Careful steps were taken to treat all the formulations quantitatively equal to maintain standards for independent testing.

Ygiene(TM) was the only antimicrobial to show absolutely no sign of corrosion. All the other solutions exhibited clear signs of chemical reaction with the steel wool, including at least one of the following events: color change in the solution, precipitation of an undetermined substance from the solution, disintegration of the steel wool into filings, deposition on the steel wool, dissolution of the steel wool, effervescence from the steel wool or the filings.

Dr. Samuel D'Arcangelis, PhD, President of Criterion Chemical, stated: "It is truly remarkable that BioNeutral's Ygiene(TM) which contains no corrosion inhibitors was completely inert and showed no signs of corrosion in the twelve day test we conducted."

"This is an important test," said Dr. Andy Kielbania PhD, Chief Scientific Officer of Bioneutral "because of the potential for Ygiene(TM) to be used as a sterilant for medical, dental and surgical instruments as well as its use on ferrous materials which are common in the broader health care field, industrial and consumer environment. It adds a further quality to the rapid sterilizing capabilities of Ygiene(TM) which separates our technology from every competitor."

"Antimicrobials are notoriously corrosive," said Stephen J. Browand BioNeutral Group's CEO. "Commercially, there are many circumstances where a green, inert, sporicidal antimicrobial will be preferred when corrosion is a concern. As an example. medical, dental and surgical instruments are expensive and their usable life is shortened by corrosion. The pharmaceutical industry mixes basic ingredients in large stainless steel vats which can be damaged by corrosive antimicrobials."

About Criterion Chemical LLC:

Criterion Chemical is a specialty chemical company with strong expertise in understanding the reactivity of metals and the mechanism of metallic catalytic processes. In addition Criterion Chemical custom synthesizes new catalyst and has unique processes for metal recovery.

About BioNeutral:

Headquartered at the New Jersey Institute of Technology/EDC in Newark, New Jersey, BioNeutral Group, Inc., is a chemical technology-based Life Science company that intends to commercialize a combinational chemistry-based technology which can neutralize harmful environmental contaminants, toxins and dangerous micro-organisms including bacteria, viruses, mold, fungi and spores. The formulations, including Ygiene(TM) and Ogiene(TM), which are eco-friendly and include natural and common ingredients which are found in baby products and in every day foods. BioNeutral has combined these widely-used compounds in highly specialized ways to create products that dramatically enhance disinfecting and cleaning results; products include BioNeutralizers and ChemoNeutralizers. BioNeutral's proprietary platform technology has been proven effective in surface, water and airborne applications.

More information about the Company may be found at www.bioneutralgroup.com.

Forward-Looking Statements

BioNeutral routinely tests its formulations against those of its competitors. The results are published to let shareholders know how BioNeutral's technology compares with known formulations in the market place. Any product claim for antimicrobial activity requires approval from the EPA or FDA, depending upon where and how the formulations are used. The EPA and FDA have not reviewed or confirmed the BioNeutral's data and findings. BioNeutral's antimicrobial formulations will be marketed under the brand name Ygiene(TM) and are not yet available for sale in the United States.

Contact Information

    BioNeutral Group Inc.
    Stephen J. Browand, President and CEO
    steve@bioneutralgroup.com

    Investor Relations
    Aimee Boutcher
    973 239-2878
    aboutcher@aol.com


'/>"/>
SOURCE BioNeutral Group, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. BioNeutrals Ygiene(TM) Hospital Grade Achieves a 100% Total Kill (Pass) Against the Life Threatening Clostridium Difficile (C.diff) Spores in Independent EPA Required Protocol Testing.
2. BioNeutrals Ygiene(TM) Hospital Grade Achieves World Class Independent Test Results in Killing Life Threatening Spores/Organisms
3. BioNeutrals Ygiene(TM) Hospital Grade Antimicrobial Demonstrates a 99.9997% Kill Rate Against Clostridium Difficile Spores (C.diff) in Independent Lab Pre-testing Phase
4. BioNeutrals Ygiene(TM) New Hospital Grade Disinfectant Will Save Lives and Billions of Dollars Annually at Health Care Facilities Around the World
5. SmartGenes Services for Faster, More Precise Identification of Bacteria and Fungi to be Used by The Johns Hopkins Hospital
6. St. Johns Hospital Acquires Latest Technology in Robotic-Assisted Surgery
7. Quantros ACE Helps East Jefferson General Hospital Achieve Best-in-Class Performance
8. USC Hospitals Extend Relationship With Quantros to Manage Compliance and Risk
9. Stem Cell Cord Blood Banking Is Huge Global Business for Hospitals, Says CEO of Bio-Matrix Scientific Group Inc.
10. Galichia Heart Hospital Partners with Mobile Surgery International to Develop Wichita-based Center of Excellence with Global Convenience(TM)
11. GeoVax Signs HIV/AIDS Vaccine Proposal With Health and Hospital System of Cook County, Illinois
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/11/2017)... 11, 2017  VMS BioMarketing, a leading provider of patient ... Clinical Nurse Educator (CNE) network, which will launch this week. ... among health care professionals to enhance the patient care experience ... and other health care professionals to help women who have ... ...
(Date:10/10/2017)... ... , ... San Diego-based team building and cooking events company, Lajollacooks4u, has unveiled ... bold new look is part of a transformation to increase awareness, appeal to new ... , It will also expand its service offering from its signature gourmet cooking classes ...
(Date:10/10/2017)... Calif. , Oct. 10, 2017 SomaGenics ... from the NIH to develop RealSeq®-SC (Single Cell), expected ... for profiling small RNAs (including microRNAs) from single cells ... Program highlights the need to accelerate development of approaches ... "New techniques for measuring levels ...
(Date:10/9/2017)... ... October 09, 2017 , ... At its national board meeting in ... professor in Harvard University’s Departments of Physics and Astronomy, has been selected for membership ... the winning team for the 2015 Breakthrough Prize in Fundamental physics for the discovery ...
Breaking Biology Technology:
(Date:4/11/2017)... , April 11, 2017 Crossmatch®, a ... authentication solutions, today announced that it has been ... Research Projects Activity (IARPA) to develop next-generation Presentation ... "Innovation has been a driving force ... program will allow us to innovate and develop ...
(Date:4/6/2017)... 6, 2017 Forecasts by Product ... Readers, by End-Use (Transportation & Logistics, Government & Public ... & Fossil Generation Facility, Nuclear Power), Industrial, Retail, Business ... Are you looking for a definitive report on ... ...
(Date:4/4/2017)... YORK , April 4, 2017   EyeLock ... today announced that the United States Patent and Trademark ... patent broadly covers the linking of an iris image ... same transaction) and represents the company,s 45 th ... latest patent is very timely given the multi-modal biometric ...
Breaking Biology News(10 mins):